Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, ...

Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation ...

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favora ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB ("BioInven ...

The ongoing Phase I/IIa study (NCT04725331) is a multicenter, open label, dose-escalation study evaluating BT-001 as a single agent and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

Raleigh-based Focal Medical, an oncology device company that received early funding from the North Carolina Biotechnology Center, has been acquired by a Florida biopharmaceutical company. Financial ...